Table 2.

Comparison of maximum post-BD-FEV1% between patients treated with and without daily oral GCs among the HSD3B1(1245) AA, AC, and CC genotypes*

SARP IIISARP I & II
HSD3B1(1245) GenotypeNot on GCOn GCP valueNot on GCOn GCP value
AA
  n123234535
  Pre-FEV1, % of predicted value75.1 ± 18.354.3 ± 15.3<0.00163.4 ± 18.849.8 ± 17.10.001
  Post-FEV1, % of predicted value83.9 ± 18.864.2 ± 19.6< 0.00173.5 ± 15.963.7 ± 18.40.024
AC
  n107244930
  Pre-FEV1, % of predicted value75.6 ± 21.259.4 ± 19.80.00166.9 ± 22.354.3 ± 18.30.008
  Post-FEV1, % of predicted value83.2 ± 20.567.7 ± 17.9<0.00177.2 ± 20.867.8 ± 20.30.07
CC
  n3381510
  Pre-FEV1, % of predicted value78.9 ± 16.373.4 ± 16.60.4167.7 ± 22.566.7 ± 26.60.92
  Post-FEV1, % of predicted value89.2 ± 17.083.1 ± 14.40.3278.2 ± 22.380.7 ± 16.20.76
  • * Data are presented as mean ± SD for continuous variables and proportions or percentages for categorical variables.

  • P value comparing daily oral GC vs. no GC in each genotype group AA, AC, and CC.